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Purpose of the study
The characteristics that distinguish disseminated MTB and
NTM infection in patients with advanced HIV disease
remain poorly studied. We aim to describe clinical, labo-
ratory and radiological features of MTB and NTM and
identify discriminatory findings.
Methods
We conducted a retrospective case note review of all
patients with culture-proven disseminated mycobacterial
disease at a UK centre from 2005–2007. Patients with
infection in ≥2 non-contiguous sites, or positive blood or
bone marrow cultures, were included and stratified by
causative pathogen. Categorical data were analysed by
Fisher's exact test and non-categorical data by rank sum
test.
Summary of results
Of the 64 patients with confirmed mycobacterial infec-
tion, 31 had disseminated disease (MTB:21, NTM:10
[nine due to M. avium Complex]). Of these, 81% were
black African, 45% male, and median age was 34 years.
Patients with NTM had lower CD4 T-cell counts, more
prior or concurrent AIDS-defining illnesses, and were
more frequently taking HAART at the time of mycobacte-
rial diagnosis. Six NTM infections and one MTB infection
appeared to be unmasked by HAART. Clinical features at
presentation were non-discriminatory. On imaging,
patients with MTB more often had parenchymal lung dis-
ease, whilst thoracic and abdominal lymphadenopathy
was common in both groups. None of the patients with
NTM had AFB smear positive respiratory specimens.
Whereas the yield of blood cultures was low in patients
with MTB, bone marrow specimens were diagnostic in all
patients. Mortality was 8% for MTB and 30% for NTM
cases. Immune reconstitution disease was observed in
52% of MTB and 30% of NTM patients. (Table 1.)
Conclusion
Clinical and laboratory characteristics of patients with
MTB and NTM overlap. In patients with suspected dissem-
inated mycobacterial infection, prior or concurrent AIDS
defining illnesses and recent HAART initiation favour
NTM, while >100 CD4 T-cells/mm3 and parenchymal
lung disease are suggestive of MTB.
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MTB (n = 21) NTM (n = 10) p value
Prior/concurrent AIDS-defining illness (%) 2(10) 7(70) 0.001
Median CD4 count at MTB/NTM diagnosis, cells/mm3 (IQR) 51(13–142) 20(5–33) 0.049
On HAART at MTB/NTM diagnosis (%) 3(14) 6(60) 0.015
Parenchymal lung disease on CT scan* (%) 17(90) 4(44) 0.02
Thoracic/abdominal lymphadenopathy on CT or US scan* (%) 19(91) 8(80) 0.577
Positive AFB smear on sputum/BAL* (%) 7(44) 0(0) NA
Positive sputum/BAL culture* (%) 12(86) 6(86) 1
Positive blood culture* (%) 1(11) 6(86) 0.009
Positive bone marrow culture and/or histology* (%) 6(100) 7(100) NA
*In those who had investigation(s) performed.Page 2 of 2
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